Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’

by Vastesaeger, Nathan, Fautrel, Bruno, Smolen, Josef
Published in Arthritis Res Ther (2015)

Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'

by Vander Cruyssen, Bert, Durez, Patrick, Westhovens, Rene, Vastesaeger, Nathan, Geldhof, Anja, De Keyser, Filip
Published 2006

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study

by Baranauskaite, Asta, Raffayová, Helena, Kungurov, NV, Kubanova, Anna, Venalis, Algirdas, Helmle, Laszlo, Srinivasan, Shankar, Nasonov, Evgeny, Vastesaeger, Nathan
Published 2011

Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up

by Bruges-Armas, Jácome, Bettencourt, Bruno F., Couto, Ana R., Lima, Manuela, Rodrigues, Ana M., Vastesaeger, Nathan, Brown, Matthew A.
Published in Case Rep Rheumatol (2014)

The epidemiology of ankylosing spondylitis and the commencement of anti‐TNF therapy in daily rheumatology practice

by Cruyssen, Bert Vander, Ribbens, Clio, Boonen, Annelies, Mielants, Herman, de Vlam, Kurt, Lenaerts, Jan, Steinfeld, Serge, Van den Bosch, Filip, Dewulf, Lode, Vastesaeger, Nathan
Published 2007

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

by Combe, Bernard, Dasgupta, Bhaskar, Louw, Ingrid, Pal, Sarvajeet, Wollenhaupt, Jürgen, Zerbini, Cristiano A F, Beaulieu, Andre D, Schulze-Koops, Hendrik, Durez, Patrick, Yao, Ruji, Vastesaeger, Nathan, Weng, Haoling H
Published 2014

Predicting the outcome of ankylosing spondylitis therapy

by Vastesaeger, Nathan, van der Heijde, Désirée, Inman, Robert D, Wang, Yanxin, Deodhar, Atul, Hsu, Benjamin, Rahman, Mahboob U, Dijkmans, Ben, Geusens, Piet, Vander Cruyssen, Bert, Collantes, Eduardo, Sieper, Joachim, Braun, Jürgen
Published 2011

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

by Cruyssen, Bert Vander, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van den Bosch, Filip, Mielants, Herman, De Clerck, Luc, Peretz, Ann, Malaise, Michel, Verbruggen, Leon, Vastesaeger, Nathan, Geldhof, Anja, Boullart, Luc, De Keyser, Filip
Published 2006

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab...

by Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van den Bosch, Filip, Veys, Eric M, Mielants, Herman, De Clerck, Luc, Peretz, Anne, Malaise, Michel, Verbruggen, Leon, Vastesaeger, Nathan, Geldhof, Anja, Boullart, Luc, De Keyser, Filip
Published 2005

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab

by Vastesaeger, Nathan, Kutzbach, Abraham Garcia, Amital, Howard, Pavelka, Karel, Lazaro, María Alicia, Moots, Robert J., Wollenhaupt, Jürgen, Zerbini, Cristiano A. F., Louw, Ingrid, Combe, Bernard, Beaulieu, Andre, Schulze-Koops, Hendrik, Dasgupta, Bhaskar, Fu, Bo, Huyck, Susan, Weng, Haoling H., Govoni, Marinella, Durez, Patrick
Published in Rheumatology (Oxford) (2016)